

Appendix, TABLE 1 Patient demographics, Safety Analysis Population from ESTABLISH-1 and ESTABLISH-2

Parameter	Tedizolid 200 mg QD (N = 662)	Linezolid 600 mg BID (N = 662)
Age, y		
n	662	662
Mean (SD)	44.6 (15.40)	44.4 (15.37)
Median	45.0	44.0
(Min, Max)	(17, 86)	(15, 100)
Age group, y, n (%)		
<18	1 (0.2)	1 (0.2)
18-65	597 (90.2)	606 (91.5)
<65	590 (89.1)	603 (91.1)
≥65	72 (10.9)	59 (8.9)
≥75	24 (3.6)	25 (3.8)
Sex, n (%)		
Male	429 (64.8)	408 (61.6)
Female	233 (35.2)	254 (38.4)
Weight, kg		
n	662	662
Mean (SD)	83.3 (21.63)	83.5 (19.87)
Median	80.0	81.0
(Min, Max)	(38, 226)	(38, 204)
BMI, kg/m ²		
n	662	662
Mean (SD)	28.2 (6.74)	28.4 (6.18)
Median	27.2	27.3
(Min, Max)	(14, 70)	(15, 56)
BMI subgroup, n (%)		
Underweight (BMI <18.5 kg/m ²)	12 (1.8)	7 (1.1)
Normal/overweight (BMI ≥18.5 and <30 kg/m ²)	450 (68.0)	426 (64.4)
Obese (BMI ≥30 kg/m ²)	200 (30.2)	229 (34.6)
Diabetes, n (%)	58 (8.8)	67 (10.1)
Race, n (%)		
American Indian or Alaska Native	7 (1.1)	9 (1.4)
Black or African American	77 (11.6)	71 (10.7)
Asian	6 (0.9)	14 (2.1)
Native Hawaiian or Other Pacific Islander	2 (0.3)	3 (0.5)
White	563 (85.0)	555 (83.8)
Other	7 (1.1)	10 (1.5)
Ethnicity, n (%)		
Hispanic	182 (27.5)	170 (25.7)
Non-Hispanic	480 (72.5)	492 (74.3)

BID, twice daily; BMI, body mass index; QD, once daily; SD, standard deviation.

Note: Patients with multiple rate entries are categorized as Other.